Skip to content

Studying how cholesterol problems are related to kidney damage in people with type 2 diabetes

Correlation of apolipoprotien B and dyslipidemia with protienuria in type 2 diabetes mellitus patient. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/100968
Enrollment
150
Registered
2026-01-13
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Department of medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patient with type 2 diabetes mellitus diagnosed with ADA 2025 guidelines

Exclusion criteria

Exclusion criteria: Age below 18 years. Type 2 Diabetes Mellitus patients with concomitant diseases or conditions affecting the lipid levels such as-Hypothyroidism , Familial dyslipidemia, familial hypercholesterolemia, alcoholics to avoid false increase in apolipoproteins. patient with Active liver disease patients on dialysis patients on lipid lowering drugs within 6 weeks and weight reducing diet pregnant and lactating female patients

Design outcomes

Primary

MeasureTime frame
The study found that higher ApoB levels and atherogenic dyslipidemia are significantly associated with increased proteinuria in Type 2 Diabetes Mellitus patients. ApoB showed a stronger correlation with proteinuria than traditional lipid parameters, indicating it may be a better marker of early kidney involvement in diabetic patientsTimepoint: Baseline

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactArshdeep kaur saggi

Sri Guru Ram das institute of medical sciences and research

chandey96098@yahoo.com9872071231

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026